Marie McCormick

Dr. McCormick was a panelist for the Forum’s discussions on Trust in VaccinesDelaying Pregnancy and Parenthood, and Marijuana: The Latest Scientific Findings and Legalization.

Marie McCormick is a pediatrician with a second doctorate in health services research. Her research has focused on the effectiveness of perinatal and neonatal health services on the health of women and children with a particular concern in the outcomes of very premature infants.  She has been a senior investigator on the evaluations of two national demonstration programs (the Robert Wood Johnson Foundation National Perinatal Regionalization Program, and currently the federal Healthy Start Program), and of an important project in Central Harlem on enhancing access to preventive services for low-income pregnant women and infants.  In addition, she has provided significant scientific, input, in a variety of roles, to the design and conduct of Infant Health and Development Project, the largest, multisite randomized trials of early childhood educational intervention, in particular, serving as the principal investigator of the follow-up at eighteen years of age.

Recent awards include election to the Johns Hopkins Society of Scholars (1995), the Ambulatory Pediatric Association Research Award (1996), the Douglas K. Richardson Award from the Society of Pediatric Research (2006), Henry Ingersoll Bowditch Award for Excellence in Public Health of the Massachusetts Medical Society and an honorary doctorate in humane letters from Emmanuel College.  She is a member of the Institute of Medicine and has served on several advisory and study panels there for which she has been recognized as a National Associate of the National Academies in recognition for exceptional pro bono service.

She served as the Chair of an Institute of Medicine committee on immunization safety for which she received the David Rall Medal from that Institute.  She has also served as a member of the National Vaccine Advisory Committee, co-chairing working groups on surveillance of the risks of the H1N1 2009 influenza immunization program and on a white paper on vaccine safety.